

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	5	"6037347"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/02/14 10:20
L2	1873	"aricept" or "donepezil"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/02/14 10:20
L3	0	l2 near parkinson	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/02/14 10:20
L4	969	l2 and parkinson	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/02/14 10:21
L5	19	"aricept".clm.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/02/14 10:21
L6	14	"aricept".clm. and "parkinson"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/02/14 10:23
L7	82	"donepezil".clm. and "parkinson"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/02/14 10:32
L8	15	"6087392"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/02/14 12:05

## EAST Search History

L9	125	"4,895,841"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/02/14 12:05
----	-----	-------------	--	----	-----	------------------

=> file registry  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.42	0.42

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 10:14:42 ON 14 FEB 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 FEB 2007 HIGHEST RN 920805-97-6  
DICTIONARY FILE UPDATES: 13 FEB 2007 HIGHEST RN 920805-97-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006


Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10806409.str



chain nodes :

10 11 18 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42  
43 44 45 46 47 48 49

ring nodes :

1 2 3 4 5 6 7 8 9 12 13 14 15 16 17 19 20 21 22 23 24

chain bonds :

1-28 2-26 3-25 4-27 7-10 8-11 8-31 9-29 9-30 11-12 11-32 11-33 12-34  
13-35 13-36 14-37 14-38 15-18 16-39 16-40 17-41 17-42 18-19 18-43 18-44  
20-45 21-46  
22-47 23-48 24-49

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 12-13 12-17 13-14 14-15 15-16  
16-17 19-20 19-24 20-21 21-22 22-23 23-24

exact/norm bonds :

5-7 6-9 7-8 7-10 8-9 12-13 12-17 13-14 14-15 15-16 15-18 16-17

exact bonds :

1-28 2-26 3-25 4-27 8-11 8-31 9-29 9-30 11-12 11-32 11-33 12-34 13-35  
13-36 14-37 14-38 16-39 16-40 17-41 17-42 18-19 18-43 18-44 20-45 21-46  
22-47 23-48  
24-49

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 19-20 19-24 20-21 21-22 22-23 23-24

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:Atom  
20:Atom 21:Atom  
22:Atom 23:Atom 24:Atom 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS  
30:CLASS 31:CLASS  
32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS  
40:CLASS 41:CLASS  
42:CLASS 43:CLASS 44:CLASS 45:CLASS 46:CLASS 47:CLASS 48:CLASS 49:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 10:15:00 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 20 TO ITERATE

100.0% PROCESSED 20 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 132 TO 668

PROJECTED ANSWERS: 1 TO 80


L2 1 SEA SSS SAM L1

=> d 12

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 880084-98-0 REGISTRY  
ED Entered STN: 11 Apr 2006  
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C24 H29 N O3 . C4 H4 O4  
SR CA  
LC STN Files: CA, CAPLUS, CASREACT, USPATFULL

CM 1


CRN 120014-06-4  
CMF C24 H29 N O3



CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.



3 REFERENCES IN FILE CA (1907 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s 11 exa full  
FULL SEARCH INITIATED 10:15:25 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 40 TO ITERATE


100.0% PROCESSED 40 ITERATIONS  
SEARCH TIME: 00.00.01

6 ANSWERS

L3 6 SEA EXA FUL L1

=> d scan


L3 6 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI)  
 MF C24 H29 N O3  
 CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 6 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN 1H-Inden-1-one-2-<sup>14</sup>C, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI)  
 MF C24 H29 N O3  
 CI COM




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 6 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN 1H-Inden-1-one, 2,3-dihydro-6-methoxy-5-(methoxy-<sup>11</sup>C)-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI)  
 MF C24 H29 N O3



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L3 6 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 1H-Inden-1-one, 2,3-dihydro-5-methoxy-6-(methoxy-11C)-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI)  
MF C24 H29 N O3



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 6 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, (2R)- (9CI)  
MF C24 H29 N O3  
CI COM

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 6 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, (2S)- (9CI)  
MF C24 H29 N O3  
CI COM

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> file medline, caplus, wpids, uspatfull

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

60.65

61.07

FILE 'MEDLINE' ENTERED AT 10:15:55 ON 14 FEB 2007

FILE 'CAPLUS' ENTERED AT 10:15:55 ON 14 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 10:15:55 ON 14 FEB 2007

COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 10:15:55 ON 14 FEB 2007

CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> d his

(FILE 'HOME' ENTERED AT 10:13:17 ON 14 FEB 2007)

FILE 'REGISTRY' ENTERED AT 10:14:42 ON 14 FEB 2007

L1 STRUCTURE UPLOADED

L2 1 S L1

L3 6 S L1 EXA FULL

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 10:15:55 ON 14 FEB 2007

=> s l3

SAMPLE SEARCH INITIATED 10:16:05 FILE 'WPIDS'

SAMPLE SCREEN SEARCH COMPLETED - 13 TO ITERATE

100.0% PROCESSED 13 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 22 TO 238

PROJECTED ANSWERS: 3 TO 81

L4 919 L3

=> s l4 not py>2000

L5 96 L4 NOT PY>2000

=> s l5 and parkinson

L6 2 L5 AND PARKINSON

=> d l6 1-2 ibib, abs, hitstr

L6 ANSWER 1 OF 2 USPATFULL on STN



ACCESSION NUMBER: 2000:31421 USPATFULL Full-text  
TITLE: Combination preparation for use in dementia  
INVENTOR(S): Schubert, Hans-Peter, Apfeldorf, Germany, Federal  
Republic of  
Nimmesgern, Hildegard, Darmstadt, Germany, Federal  
Republic of  
Rudolphi, Karl, Mainz, Germany, Federal Republic of  
PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft, Frankfurt am Main, Germany,  
Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6037347		20000314
APPLICATION INFO.:	US 1998-30207		19980225 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1997-19707655	19970226
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Gitomer, Ralph	
ASSISTANT EXAMINER:	Moran, Marjorie A.	
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	19	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	543	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a composition which is a pharmaceutical combination preparation comprising a compound which has an acetylcholinesterase-inhibitory action or exhibits muscarinergic action and a compound which increases the endogenous extracellular adenosine level, wherein the combination preparation is suitable for the treatment of dementia. The invention further relates to a process for the production of the combination preparation. The invention additionally relates to a process for treating patients in need of suitable therapy with the combination preparation.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 120014-06-4

(combined preparation for treatment of dementia)

RN 120014-06-4 USPATFULL

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 2 USPATFULL on STN

ACCESSION NUMBER: 1999:155706 USPATFULL Full-text

TITLE: Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and

prophylactic uses thereof  
INVENTOR(S): Gerolymatos, Panayotis N., Kryoneri Attikis, Greece  
PATENT ASSIGNEE(S): P.N. Gerolymatos S.A., Kryoneri Attikis, Greece  
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5994323		19991130
APPLICATION INFO.:	US 1998-23542		19980213 (9)


	NUMBER	DATE
PRIORITY INFORMATION:	GR 1997-970100507	19971231
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Criares, Theodore J.	
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	1039	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical composition is disclosed that comprises clioquinol, vitamin B.sub.12, and, optionally, pharmaceutical acceptable carriers and/or excipients. The use of the pharmaceutical composition removes or alleviates the side effects of clioquinol.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 120014-06-4, Donepezil  
(phanquinone and other agents for the treatment of Alzheimer's disease)  
RN 120014-06-4 USPATFULL  
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



=> s "donepezil" or "aricept"

L7 4186 "DONEPEZIL" OR "ARICEPT"

=> s 17 and "parkinson"

L8 1061 L7 AND "PARKINSON"

=> s 18 not py>2000

L9 17 L8 NOT PY>2000

=> d 19 1-17 ibib, abs

L9 ANSWER 1 OF 17 MEDLINE on STN

ACCESSION NUMBER: 1999154200 MEDLINE Full-text

DOCUMENT NUMBER: PubMed ID: 10029938  
TITLE: Donepezil for dementia with Lewy bodies: a case study.  
AUTHOR: Aarsland D; Bronnick K; Karlsen K  
SOURCE: International journal of geriatric psychiatry, (1999 Jan) Vol. 14, No. 1, pp. 69-72.  
Journal code: 8710629. ISSN: 0885-6230.  
PUB. COUNTRY: ENGLAND: United Kingdom  
DOCUMENT TYPE: (CASE REPORTS)  
Letter  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199904  
ENTRY DATE: Entered STN: 11 May 1999  
Last Updated on STN: 11 May 1999  
Entered Medline: 23 Apr 1999

L9 ANSWER 2 OF 17 MEDLINE on STN  
ACCESSION NUMBER: 1999028666 MEDLINE Full-text  
DOCUMENT NUMBER: PubMed ID: 9812132  
TITLE: Violent behavior-associated with donepezil.  
AUTHOR: Bouman W P; Pinner G  
SOURCE: The American journal of psychiatry, (1998 Nov) Vol. 155, No. 11, pp. 1626-7.  
Journal code: 0370512. ISSN: 0002-953X.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: (CASE REPORTS)  
Letter  
LANGUAGE: English  
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
ENTRY MONTH: 199811  
ENTRY DATE: Entered STN: 6 Jan 1999  
Last Updated on STN: 6 Jan 1999  
Entered Medline: 23 Nov 1998

L9 ANSWER 3 OF 17 MEDLINE on STN  
ACCESSION NUMBER: 1999001323 MEDLINE Full-text  
DOCUMENT NUMBER: PubMed ID: 9785144  
TITLE: Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients.  
AUTHOR: Shea C; MacKnight C; Rockwood K  
CORPORATE SOURCE: Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia Canada.  
SOURCE: International psychogeriatrics / IPA, (1998 Sep) Vol. 10, No. 3, pp. 229-38.  
Journal code: 9007918. ISSN: 1041-6102.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: (CASE REPORTS)  
(CLINICAL TRIAL)  
(CONTROLLED CLINICAL TRIAL)  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199812  
ENTRY DATE: Entered STN: 15 Jan 1999  
Last Updated on STN: 3 Mar 2000  
Entered Medline: 11 Dec 1998

AB Dementia with Lewy bodies (DLB) is common. Symptomatic treatment can be difficult. We reviewed nine consecutive patients with DLB (mean age 77.5 [range 67 to 84] years; seven men and two women; mean duration of disease 3.7

[range 1.5 to 8.0] years) who had been treated with donepezil . Each initially received 2.5 to 5 mg per day of donepezil, and was stabilized on 5 mg per day. Donepezil was increased to 10 mg per day in five patients. The mean observation period was 12 (range 8 to 24) weeks. Target symptoms included cognition, hallucinations, parkinsonism, and functional abilities. By both cognitive testing and family reports, cognition improved in seven of nine patients, remained the same in one of nine, and fluctuated in one of nine (mean Mini-Mental State Examination change 4.4 +/- 6.3 points). Function was improved or maintained in six of nine patients and fluctuated in two of nine. Hallucinations initially worsened, then fluctuated in one patient, but improvement in frequency, duration, and content was reported in eight of nine cases. In three of nine patients, treatment with donepezil resulted in worsening of parkinsonism, which in each case responded to levodopa/carbidopa. Treatment of DLB patients with donepezil for 12 weeks most commonly improved hallucinations, and sometimes improved cognition and overall function. Treatment with donepezil was sometimes associated with worse parkinsonism.

L9 ANSWER 4 OF 17 MEDLINE on STN  
 ACCESSION NUMBER: 1998456516 MEDLINE Full-text  
 DOCUMENT NUMBER: PubMed ID: 9783187  
 TITLE: [50th Annual Meeting of the American Academy of Neurology (AAN). Minneapolis, 25 April--2 May 1998. 151st Annual Meeting of the American Psychiatric Association (APA). Toronto, 31 May--3 June 1998].  
 50th Annual Meeting of the American Academy of Neurology (AAN) Minneapolis, 25. April bis 2. Mai 1998. 151st Annual Meeting of the American Psychiatric Association (APA) Toronto, 31. Mai bis 3. Juni 1998.  
 AUTHOR: Anonymous  
 SOURCE: Fortschritte der Neurologie-Psychiatrie, (1998 Sep) Vol. 66, No. 9 Suppl, pp. 1-8.  
 Journal code: 8103137. ISSN: 0720-4299..  
 PUB. COUNTRY: GERMANY: Germany, Federal Republic of  
 DOCUMENT TYPE: Conference; Conference Article; (CONGRESSES)  
 LANGUAGE: German  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 199810  
 ENTRY DATE: Entered STN: 6 Jan 1999  
 Last Updated on STN: 6 Jan 1999  
 Entered Medline: 27 Oct 1998

L9 ANSWER 5 OF 17 MEDLINE on STN  
 ACCESSION NUMBER: 1998269331 MEDLINE Full-text  
 DOCUMENT NUMBER: PubMed ID: 9606486  
 TITLE: Possible association between donepezil and worsening Parkinson's disease.  
 AUTHOR: Bourke D; Druckenbrod R W  
 SOURCE: The Annals of pharmacotherapy, (1998 May) Vol. 32, No. 5, pp. 610-1.  
 Journal code: 9203131. ISSN: 1060-0280.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: (CASE REPORTS)  
 Letter  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 199807  
 ENTRY DATE: Entered STN: 11 Aug 1998  
 Last Updated on STN: 11 Aug 1998  
 Entered Medline: 30 Jul 1998

L9 ANSWER 6 OF 17 MEDLINE on STN  
 ACCESSION NUMBER: 1998260645 MEDLINE Full-text  
 DOCUMENT NUMBER: PubMed ID: 9598283  
 TITLE: Combination of risperidone and donepezil in Lewy  
 body dementia.  
 AUTHOR: Geizer M; Ancill R J  
 SOURCE: Canadian journal of psychiatry. Revue canadienne de  
 psychiatrie, (1998 May) Vol. 43, No. 4, pp. 421-2.  
 Journal code: 7904187. ISSN: 0706-7437.  
 PUB. COUNTRY: Canada  
 DOCUMENT TYPE: (CASE REPORTS)  
 Letter  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 199808  
 ENTRY DATE: Entered STN: 20 Aug 1998  
 Last Updated on STN: 20 Aug 1998  
 Entered Medline: 10 Aug 1998

L9 ANSWER 7 OF 17 USPATFULL on STN  
 ACCESSION NUMBER: 2000:174658 USPATFULL Full-text  
 TITLE: Method for controlling tobacco use and alleviating  
 withdrawal symptoms due to cessation of tobacco use  
 INVENTOR(S): Viner, Norman, Ottawa, Canada  
 PATENT ASSIGNEE(S): Synapse Pharmaceuticals International, Inc., Ottawa,  
 Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6166032		20001226
APPLICATION INFO.:	US 1997-797251		19970207 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Criares, Theodore J.		
NUMBER OF CLAIMS:	32		
EXEMPLARY CLAIM:	1		
LINE COUNT:	611		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for controlling tobacco use and alleviating withdrawal symptoms due to the cessation of tobacco use comprising administering to a human desiring to control tobacco use and/or suffering from withdrawal due to cessation of such use an effective amount of an acetylcholine esterase reactivator or prodrug derivative thereof optionally in association with an acetylcholine receptor antagonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 17 USPATFULL on STN  
 ACCESSION NUMBER: 2000:169089 USPATFULL Full-text  
 TITLE: Method and apparatus for treating chronic pain  
 syndromes, tremor, dementia and related disorders and  
 for inducing electroanesthesia using high frequency,  
 high intensity transcutaneous electrical nerve  
 stimulation  
 INVENTOR(S): Silverstone, Leon M., La Jolla, CA, United States  
 PATENT ASSIGNEE(S): Synaptic Corporation, Aurora, CO, United States (U.S.  
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6161044		20001212
APPLICATION INFO.:	US 1998-199073		19981123 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kamm, William E.		
LEGAL REPRESENTATIVE:	Fitch, Even, Tabin & Flannery		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	1249		

AB Provided herein is a non-invasive method of treating, controlling or preventing medical, psychiatric or neurological disorders, using transcutaneous electrical stimulation. The method employs a plurality of stimulation frequency parameters, ranging from a relatively high frequency, for example about 40,000 Hertz, to a relatively low frequency, for example about 250 Hertz, the entire plurality of frequency parameters being administered at each of a plurality of stimulation intensity levels. In particular, the method involves stimulating at a first highest frequency parameter and a first lowest intensity parameter, incrementally decreasing the stimulation frequency parameter a lowest frequency parameter, increasing the frequency parameter to the highest frequency parameter and increasing the intensity parameter to a next highest intensity parameter, and again stimulating through the plurality of frequency parameters from the highest frequency to the lowest frequency. The method described herein is useful in treating, controlling and/or preventing various disease states and disorders, including without limitation, tremor disorders, such as essential tremor and Parkinson's disease, dementia disorders, such as Alzheimer's disease and painful degenerative disorders, such as reflex sympathetic dystrophy and fibromyalgia.

L9 ANSWER 9 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2000:164554 USPATFULL Full-text  
 TITLE: Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives  
 INVENTOR(S): Reiter, Lawrence A., Mystic, CT, United States  
 PATENT ASSIGNEE(S): Pfizer Inc, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6156798		20001205
APPLICATION INFO.:	US 1999-290023		19990409 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-81392P	19980410 (60)
	US 1997-55208P	19970808 (60)
	US 1997-55207P	19970808 (60)
	US 1997-62766P	19971024 (60)
	US 1997-68261P	19971219 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Richter, Johann	
ASSISTANT EXAMINER:	Davis, Brian J.	
LEGAL REPRESENTATIVE:	Richardson, Peter C., Ginsburg, Paul H., Jacobs, Seth	

H.  
NUMBER OF CLAIMS: 15  
EXEMPLARY CLAIM: 1  
LINE COUNT: 1142

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of the formula ##STR1## wherein Y and R<sup>sup.1</sup> are defined in the specification, useful in the treatment of arthritis or cancer and other diseases involving selective inhibition of matrix metalloproteinase-13.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 10 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2000:128350 USPATFULL Full-text

TITLE: Diphenylalkyl-tetrahydropyridines, process for their preparation, and pharmaceutical compositions containing them

INVENTOR(S): Baroni, Marco, Vanzago, Italy  
Cardamone, Rosanna, Como, Italy  
Fournier, Jacqueline, Plaisance du Touch, France  
Guzzi, Umberto, Milan, Italy

PATENT ASSIGNEE(S): Sanofi-Synthelabo, Paris, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6124318		20000926
	WO 9825904		19980618
APPLICATION INFO.:	US 1999-331005		19990727 (9)
	WO 1997-FR2289		19971211
			19990727 PCT 371 date
			19990727 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1996-15336	19961213
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Seaman, D. Margaret	
LEGAL REPRESENTATIVE:	Alexander, Michael D., Dupont, Paul E.	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
LINE COUNT:	748	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to compounds of the formula ##STR1## in which: Y is --CH-- or --N--;

R<sub>sub.1</sub> is a halogen or a CF<sub>sub.3</sub>, (C<sub>sub.1</sub> -C<sub>sub.4</sub>)alkyl or (C<sub>sub.1</sub> -C<sub>sub.4</sub>)alkoxy group;

R<sub>sub.2</sub> and R<sub>sub.3</sub> are each hydrogen or a (C<sub>sub.1</sub> -C<sub>sub.3</sub>)alkyl;

n is 0 or 1; and

Ph<sub>sub.1</sub> and Ph<sub>sub.2</sub> are each independently an unsubstituted, monosubstituted or polysubstituted phenyl group;

to a process for their preparation and to the pharmaceutical compositions containing them.

These compounds have neurotrophic and neuroprotective activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 11 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2000:124824 USPATFULL Full-text

TITLE: Synthetic antisense oligodeoxynucleotides targeted to human ache

INVENTOR(S): Soreq, Hermona, Jerusalem, Israel  
Seidman, Shlomo, Neve Daniel, Israel  
Eckstein, Fritz, Gottingen, Germany, Federal Republic of  
Friedman, Alon, M. Post HaNeguev, Israel  
Kaufer, Daniela, Mevasseret Zion, Israel

PATENT ASSIGNEE(S): Yissum Research Development Company of the Hebrew  
Yniversity of Jerusalem, Jerusalem, Israel (non-U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6121046		20000919
APPLICATION INFO.:	US 1997-990065		19971212 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-850347, filed on 2 May 1997 which is a continuation-in-part of Ser. No. US 318826		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-35266P	19961212 (60)
	US 1997-37777P	19970213 (60)
	US 1997-53334P	19970721 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: LeGuyader, John L.  
ASSISTANT EXAMINER: Lacourciere, Karen A.  
LEGAL REPRESENTATIVE: Kohn & Associates  
NUMBER OF CLAIMS: 14  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 12 Drawing Page(s)  
LINE COUNT: 2796

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A synthetic nuclease resistant antisense oligodeoxynucleotide (AS-ODN) capable of selectively modulating human acetylcholinesterase (AChE) production and a composition comprising at least one AS-ODN as an active ingredient. A nuclease resistant antisense targeted against the splice junction in the AChE mRNA post-splice message is disclosed. The synthetic nuclease resistant AS-ODNs are capable of selectively modulating human AChE production in the central nervous system or capable of selectively reducing human AChE deposition of the neuromuscular junction. The present invention also provides a method to restore balanced cholinergic signalling in the brain and spinal cord or reduce AChE in the neuromuscular junction in patients in need of such treatment by administering to a patient in need of such treatment a therapeutically effective amount of at least one of the



synthetic nuclease resistant AS-ODN capable of selectively modulating human AChE production.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 12 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2000:117742 USPATFULL Full-text  
TITLE: 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives  
INVENTOR(S): Robinson, Ralph P., Gales Ferry, CT, United States  
Laird, Ellen R., Mystic, CT, United States  
PATENT ASSIGNEE(S): Pfizer Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6114361		20000905
APPLICATION INFO.:	US 1999-429937		19991029 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	McKane, Joseph		
ASSISTANT EXAMINER:	Oswecki, Jane C.		
LEGAL REPRESENTATIVE:	Richardson, Peter C., Ginsburg, Paul H., Jacobs, Seth		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1761		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a compound of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 are as defined above, to pharmaceutical compositions and methods of treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 13 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2000:113991 USPATFULL Full-text  
TITLE: Bicyclic hydroxamic acid derivatives  
INVENTOR(S): Robinson, Ralph Pelton, Gales Ferry, CT, United States  
PATENT ASSIGNEE(S): Pfizer Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6110964		20000829
	WO 9952910		19991021
APPLICATION INFO.:	US 1999-402259		19990930 (9)
	WO 1999-1B503		19990324
			19990930 PCT 371 date
			19990930 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-81309P	19980410 (60)
	US 1997-55208P	19970808 (60)
	US 1997-55207P	19970808 (60)
	US 1997-62766P	19971024 (60)
	US 1997-68261P	19971219 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	

PRIMARY EXAMINER: Lambkin, Deborah C.  
LEGAL REPRESENTATIVE: Richardson, Peter C., Ginsburg, Paul H., Appleman,  
Polene W.  
NUMBER OF CLAIMS: 27  
EXEMPLARY CLAIM: 1  
LINE COUNT: 1851

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of the formula ##STR1## wherein Z and Q are as defined in the  
specification, to pharmaceutical compositions containing them and to their  
medicinal use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 14 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2000:88221 USPATFULL Full-text  
TITLE: (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid  
hydroxamides  
INVENTOR(S): Reiter, Lawrence Alan, Mystic, CT, United States  
PATENT ASSIGNEE(S): Pfizer Inc., New York, NY, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6087392		20000711
	WO 9952889		19991021
APPLICATION INFO.:	US 1999-380436		19990901 (9)
	WO 1999-IB505		19990324
			19990901 PCT 371 date
			19990901 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-81364P	19980410 (60)
	US 1997-55208P	19970808 (60)
	US 1997-55207P	19970808 (60)
	US 1997-62766P	19971024 (60)
	US 1997-68261P	19971219 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Dentz, Bernard  
LEGAL REPRESENTATIVE: Richardson, Peter C., Ginsburg, Paul H., Butterfield,  
Garth  
NUMBER OF CLAIMS: 11  
EXEMPLARY CLAIM: 1  
LINE COUNT: 1377

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of the formula ##STR1## wherein Q is as defined above, are useful  
in the treatment of a condition selected from the group consisting of  
arthritis (including osteoarthritis and rheumatoid arthritis), inflammatory  
bowel disease, Crohn's disease, emphysema, chronic obstructive pulmonary  
disease, Alzheimer's disease, organ transplant toxicity, cachexia, allergic  
reactions, allergic contact hypersensitivity, cancer, tissue ulceration,  
restenosis, periodontal disease, epidermolysis bullosa, osteoporosis,  
loosening of artificial joint implants, atherosclerosis (including  
atherosclerotic plaque rupture), aortic aneurysm (including abdominal aortic  
aneurysm and brain aortic aneurysm), congestive heart failure, myocardial  
infarction, stroke, cerebral ischemia, head trauma, spinal cord injury,  
neuro-degenerative disorders (acute and chronic), autoimmune disorders,  
Huntington's disease, Parkinson's disease, migraine, depression, peripheral

neuropathy, pain, cerebral amyloid angiopathy, nootropic or cognition enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, corneal injury, macular degeneration, abnormal wound healing, burns, diabetes, tumor invasion, tumor growth, tumor metastasis, corneal scarring, scleritis, AIDS, sepsis and septic shock. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (NSAID'S) and analgesics, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and other alkaloids, such as vincristine, in the treatment of cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 15 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2000:31421 USPATFULL Full-text  
 TITLE: Combination preparation for use in dementia  
 INVENTOR(S): Schubert, Hans-Peter, Apfeldorf, Germany, Federal Republic of  
 Nimmesgern, Hildegard, Darmstadt, Germany, Federal Republic of  
 Rudolphi, Karl, Mainz, Germany, Federal Republic of  
 PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft, Frankfurt am Main, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6037347		20000314
APPLICATION INFO.:	US 1998-30207		19980225 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1997-19707655	19970226
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Gitomer, Ralph	
ASSISTANT EXAMINER:	Moran, Marjorie A.	
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	19	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	543	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a composition which is a pharmaceutical combination preparation comprising a compound which has an acetylcholinesterase-inhibitory action or exhibits muscarinergic action and a compound which increases the endogenous extracellular adenosine level, wherein the combination preparation is suitable for the treatment of dementia. The invention further relates to a process for the production of the combination preparation. The invention additionally relates to a process for treating patients in need of suitable therapy with the combination preparation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 16 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2000:27986 USPATFULL Full-text  
 TITLE: 1-Phenylalkyl-1,2,3,6-tetrahydropyridines for treating Alzheimer's disease  
 INVENTOR(S): Baroni, Marco, Vanzago, Italy

Cardamone, Rosanna, Como, Italy  
 Fournier, Jacqueline, Plaisance Du Touch, France  
 Guzzi, Umberto, Milan, Italy  
 PATENT ASSIGNEE(S): Sanofi-Synthlabo, Paris, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6034090		20000307
	WO 9825903		19980618
APPLICATION INFO.:	US 1999-331006		19990727 (9)
	WO 1997-FR2286		19971212
			19990727 PCT 371 date
			19990727 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1996-15335	19961213
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Davis, Zinna Northington	
ASSISTANT EXAMINER:	Robinson, Binta	
LEGAL REPRESENTATIVE:	Alexander, Michael D.	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	791	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to compounds of the formula in which: Y is --CH-- or --N--; R.sub.1 is hydrogen, a halogen or a CF.sub.3, (C.sub.1 -C.sub.4)alkyl or (C.sub.1 -C.sub.4)alkoxy group; R.sub.2 is a methyl or ethyl group; R.sub.3 and R.sub.4 are each hydrogen or a (C.sub.1 -C.sub.3)alkyl; and X is:

(a) a (C.sub.1 -C.sub.6)alkyl, a (C.sub.1 -C.sub.6)alkoxy, a (C.sub.3 -C.sub.7)carboxyalkyl, a (C.sub.1 -C.sub.4)alkoxy-carbonyl(C.sub.1 -C.sub.6)alkyl, a (C.sub.3 -C.sub.7)carboxyalkoxy or a (C.sub.1 -C.sub.4)alkoxycarbonyl-(C.sub.1 -C.sub.6)alkoxy;

(b) a radical selected from (C.sub.3 -C.sub.7)cycloalkyl, (C.sub.3 -C.sub.7)cycloalkoxy, (C.sub.3 -C.sub.7)-cycloalkylmethyl, (C.sub.3 -C.sub.7)cycloalkylamino and cyclohexenyl, it being possible for said radical to be substituted by a halogen, hydroxyl, (C.sub.1 -C.sub.4)-alkoxy, carboxyl, (C.sub.1 -C.sub.4)alkoxycarbonyl, amino or mono- or di-(C.sub.1 -C.sub.4)-alkylamino; or

(c) a group selected from a phenyl, phenoxy, phenylamino, N-(C.sub.1 -C.sub.3)alkyl-phenylamino, phenylmethyl, phenylethyl, phenylcarbonyl, phenylthio, phenylsulfonyl, phenylsulfinyl and styryl, it being possible for said group to be monosubstituted or polysubstituted on the phenyl group by a halogen, CF.sub.3, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy, cyano, amino, mono- or di-(C.sub.1 -C.sub.4)alkyl- amino, (C.sub.1 -C.sub.4)acylamino, carboxyl, (C.sub.1 -C.sub.4)alkoxycarbonyl, aminocarbonyl, mono- or di-(C.sub.1 -C.sub.4)alkylaminocarbonyl, amino(C.sub.1 -C.sub.4)alkyl, hydroxy(C.sub.1 -C.sub.4)alkyl or halogeno(C.sub.1 -C.sub.4)alkyl;

to a method of preparing them and to the pharmaceutical compositions containing them. These compounds have neurotrophic and neuroprotective activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 17 OF 17 USPATFULL on STN

ACCESSION NUMBER: 1999:121436 USPATFULL Full-text  
TITLE: Composition for alzheimer's disease  
INVENTOR(S): Miyamoto, Masaomi, Hyogo, Japan  
Ohta, Hiroyuki, Osaka, Japan  
Goto, Giichi, Osaka, Japan  
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan  
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5962535		19991005
APPLICATION INFO.:	US 1998-42625		19980317 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 1998-JP109, filed on 14 Jan 1998		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1997-6147	19970117
	US 1997-65597P	19971118 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Criares, Theodore J.	
LEGAL REPRESENTATIVE:	Wenderoth, Lind & Ponack, L.L.P.	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 4 Drawing Page(s)	
LINE COUNT:	878	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical composition comprising idebenone in combination with a compound having acetylcholinesterase inhibitory activity is useful for treating or preventing Alzheimer's disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

97.28

158.35

FILE 'STNGUIDE' ENTERED AT 10:33:11 ON 14 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Feb 9, 2007 (20070209/UP).

=>

=> d his

(FILE 'HOME' ENTERED AT 10:13:17 ON 14 FEB 2007)

FILE 'REGISTRY' ENTERED AT 10:14:42 ON 14 FEB 2007

L1 STRUCTURE UPLOADED

L2 1 S L1

L3 6 S L1 EXA FULL

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 10:15:55 ON 14 FEB 2007

L4 919 S L3

L5 96 S L4 NOT PY>2000

L6 2 S L5 AND PARKINSON

L7 4186 S "DONEPEZIL" OR "ARICEPT"

L8 1061 S L7 AND "PARKINSON"

L9 17 S L8 NOT PY>2000

FILE 'STNGUIDE' ENTERED AT 10:33:11 ON 14 FEB 2007

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

2.28

160.63

STN INTERNATIONAL LOGOFF AT 10:56:16 ON 14 FEB 2007



A service of the National Library of Medicine  
and the National Institutes of Health

My NCBI [?] [\[Sign In\]](#) [\[Register\]](#)

[www.pubmed.gov](http://www.pubmed.gov)

[All Databases](#)

[PubMed](#)

[Nucleotide](#)

[Protein](#)

[Genome](#)

[Structure](#)

[OMIM](#)

[PMC](#)

[Journals](#)

[Books](#)

[Search PubMed](#)

[Preview](#)

[Go](#)

[Clear](#)

[Limits](#)

[Preview/Index](#)

**[History](#)**

[Clipboard](#)

[Details](#)

- Search History will be lost after eight hours of inactivity.
- Search numbers may not be continuous; all searches are represented.
- To save search indefinitely, click query # and select Save in My NCBI.
- To combine searches use #search, e.g., #2 AND #3 or click query # for more options.

[About Entrez](#)

[Text Version](#)

[Entrez PubMed](#)

[Overview](#)

[Help | FAQ](#)

[Tutorials](#)

[New/Noteworthy](#)

[E-Utilities](#)

## Search

## Most Recent Queries

**Time Result**

[#9](#) Search **aricept and parkinson**

10:56:09 [32](#)

[#1](#) Search **donepezil and parkinson**

10:55:33 [42](#)

[Clear History](#)

[PubMed Services](#)

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[Special Queries](#)

[LinkOut](#)

[My NCBI](#)

[Related Resources](#)

[Order Documents](#)

[NLM Mobile](#)

[NLM Catalog](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Feb 7 2007 15:04:00